Related references
Note: Only part of the references are listed.Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study
M. Ranson et al.
ANNALS OF ONCOLOGY (2010)
Pemetrexed Safety and Pharmacokinetics in Patients with Third-Space Fluid
Nicolas J. Dickgreber et al.
CLINICAL CANCER RESEARCH (2010)
Pemetrexed in advanced non-small-cell lung cancer
Alexander D. Fuld et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Therapeutics by Cytotoxic Metabolite Accumulation: Pemetrexed Causes ZMP Accumulation, AMPK Activation, and Mammalian Target of Rapamycin Inhibition
Alexandra C. Racanelli et al.
CANCER RESEARCH (2009)
Phase I and Pharmacokinetic Study of Pemetrexed plus Cisplatin in Chemonaive Patients with Locally Advanced or Metastatic Malignant Pleural Mesothelioma or Non-Small Cell Lung Cancer
Nicolas J. Dickgreber et al.
CLINICAL CANCER RESEARCH (2009)
Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer
Jyoti D. Patel et al.
CLINICAL LUNG CANCER (2009)
Intrapleural Administration of Pemetrexed A Pharmacokinetic Study in an Animal Model
Laurent Greillier et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer
M. H. Cullen et al.
ANNALS OF ONCOLOGY (2008)
Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer
Yuichiro Ohe et al.
CLINICAL CANCER RESEARCH (2008)
Current concepts in chemotherapy for malignant pleural mesothelioma
Jens Benn Sorensen
CLINICAL RESPIRATORY JOURNAL (2008)
Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer
Robert Paridaens et al.
CLINICAL BREAST CANCER (2007)
Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules
K. M. Li et al.
BRITISH JOURNAL OF CANCER (2007)
Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer
Chris H. Takimoto et al.
CLINICAL CANCER RESEARCH (2007)
Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates
Stacie L. Stapleton et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment
Jens Benn Sorensen et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies
Eric K. Rowinsky et al.
CLINICAL CANCER RESEARCH (2007)
A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer
Christian Dittrich et al.
CLINICAL CANCER RESEARCH (2006)
Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients
JE Latz et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function
AC Mita et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer
CJ Sweeney et al.
CLINICAL CANCER RESEARCH (2006)
Distribution of the novel antifolate pemetrexed to the brain
HQ Dai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors
GK Dy et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors
JL Misset et al.
ANNALS OF ONCOLOGY (2004)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
5-Fluorouracil: Mechanisms of action and clinical strategies
DB Longley et al.
NATURE REVIEWS CANCER (2003)
The effect of malignant effusions on methotrexate disposition
J Li et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Dosing strategies for anticancer drugs: the good, the bad and body-surface area
A Felici et al.
EUROPEAN JOURNAL OF CANCER (2002)
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma
A Hughes et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Folate status and the safety profile of antifolates
H Calvert
SEMINARS IN ONCOLOGY (2002)
Body surface area as a determinant of pharmacokinetics and drug dosing
M Sawyer et al.
INVESTIGATIONAL NEW DRUGS (2001)
Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors
AA Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
